Industry: Pharmaceuticals - World Trademark Review

The right tactics for the right case: how to tailor your litigation strategy to different jurisdictions

Limited financial resources, an uptick in trademark squatting and the growing risks of product piracy in the pharmaceutical space demand a closer look at the different resolution strategies being adopted by litigation experts across the globe.

14 March 2024

Sanofi’s collegiate approach to combatting genericism

Representatives from global healthcare company Sanofi speak to WTR about their recent efforts to protect the company's NANOBODY trademark from genericism.

05 February 2024

Roivant Sciences

Featured in WTR and IAM Special Report Q4 2023: IP Disruptors 2024: The companies and people driving change and upending IP norms

25 January 2024

Royalty Pharma

Featured in WTR and IAM Special Report Q4 2023: IP Disruptors 2024: The companies and people driving change and upending IP norms

25 January 2024

Nimbus Therapeutics

Featured in WTR and IAM Special Report Q4 2023: IP Disruptors 2024: The companies and people driving change and upending IP norms

25 January 2024

Owkin

Featured in WTR and IAM Special Report Q4 2023: IP Disruptors 2024: The companies and people driving change and upending IP norms

25 January 2024

General Court: Board of Appeal erred in maintaining LUTAMAX registration only for Class 5 sub-category

The court notably stressed that “dietary supplements adapted for medical or dietetic use” form a sufficiently clear category within Class 5.

22 January 2024

The US public is increasingly underestimating the dangers of buying medication online, consumer survey finds

The results of a recent survey by the Alliance for Safe Online Pharmacies suggest that news reports and awareness campaigns about counterfeit drugs and unauthorised health providers are struggling to get through to the public.

07 December 2023

Mankind not so kind to Novakind

A key finding was that the word ‘kind’ is not commonly used in the pharmaceutical industry and is not descriptive of pharmaceutical products.

24 October 2023

Supreme Court disregards tradition of cumulative protection for trademarks in pharmaceutical case

The Supreme Court’s momentous ruling on a dispute over a pharmaceutical trademark disregards the cumulative protection for marks established in previous legislation, separating protection from unfair competition provisions and eschewing well-worn precedent.

18 May 2023